Taken together these data imply that targeting ZIP6 and ZIP10, along with ZIP7, could provide an effective means of treating tamoxifen resistant (TAMR) breast cancer by impairing the availability of both intra- and extracellular zinc and attenuation of its subsequent downstream signalling. Here, SLC39A10 is linked to breast carcinoma.